CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on ...

So should Cullinan Therapeutics ( NASDAQ:CGEM) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash ...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report)’s share price gapped up before the market opened on Wednesday after HC Wainwright raised their price target on the stock from $28.00 to $33.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price objective boosted by investment analysts at HC Wainwright from $28.00 to $33.00 in a research note issued to investors on Wednesday, ...

H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $33 from $28 and keeps a Buy rating on the shares after the ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing ...

(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM;“Cullinan”), a biopharmaceutical ...